Historical source coverage
76 selected records with a cited source date in 2021. This archive is selective and does not imply continuous monitoring or complete historical coverage.
Regulatory · Abaloparatide
DailyMed lists Structured Product Labeling version 10 for the reviewed Abaloparatide label family with a published date of 2021-12-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Literature metadata · KPV
PeptideScanner retained PubMed bibliographic metadata for PMID 34846053 at 2026-07-30T19:56:20.406Z. PubMed recorded a metadata revision date of 2021-12-23 and an Entrez history date of 2021-11-30. PeptideScanner associated this retained record with the identity slug kpv. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Regulatory · Lanreotide
The official Drugs@FDA dataset lists original submission 1 for NDA 215395 with status AP dated 2021-12-17, and names lanreotide acetate among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Regulatory · Dulaglutide
DailyMed lists Structured Product Labeling version 41 for the reviewed Dulaglutide label family with a published date of 2021-12-09. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Literature metadata · Dulaglutide
PubMed lists PMID 34861012 in The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians as Journal Article, with publication-date metadata of 2018-06-25 (day precision). PeptideScanner associated the retained record with the identity slug dulaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Regulatory · Tesamorelin
DailyMed lists Structured Product Labeling version 3 for the reviewed Tesamorelin label family with a published date of 2021-12-03. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Regulatory · Vosoritide
DailyMed lists Structured Product Labeling version 8 for the reviewed Vosoritide label family with a published date of 2021-12-03. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Clinical trials · Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT03357380 at 2026-07-30T19:56:31.568Z. Its registry update date was 2021-11-22, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Regulatory · Vosoritide
The official Drugs@FDA dataset lists original submission 1 for NDA 214938 with status AP dated 2021-11-19, and names vosoritide among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Literature metadata · Abaloparatide
PubMed lists PMID 34786439 in Bone reports as Case Reports, Journal Article, with publication-date metadata of 2021-10-30 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Clinical trials · Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT03611582 at 2026-07-30T19:56:31.576Z. Its registry update date was 2021-11-11, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Regulatory · Glucagon + 1 more
The Federal Register published notice 2021-24431, attributed to FDA and its parent HHS department, on 2021-11-09. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon and Leuprolide.
Source: Federal Register via GovInfo ↗
Regulatory · Afamelanotide
The Federal Register published notice 2021-24074, attributed to FDA and its parent HHS department, on 2021-11-04. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; SCENESSE,” and PeptideScanner's exact reviewed identity mapping connects the document to Afamelanotide.
Source: Federal Register via GovInfo ↗
Clinical trials · Afamelanotide
PeptideScanner retained ClinicalTrials.gov record NCT04943159 at 2026-07-30T19:57:27.404Z. Its registry update date was 2021-10-26, and PeptideScanner's reviewed identity mapping was afamelanotide.
Source: ClinicalTrials.gov ↗
Literature metadata · Pramlintide
PubMed lists PMID 23865841 in Diabetes technology & therapeutics as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-07-18 (day precision). PeptideScanner associated the retained record with the identity slug pramlintide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Literature metadata · Semax
PubMed lists PMID 23652441 in Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-05-08 (day precision). PeptideScanner associated the retained record with the identity slug semax. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Literature metadata · Elamipretide
PubMed lists PMID 23813215 in Journal of the American Society of Nephrology : JASN as Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-07-11 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Literature metadata · Semax
PubMed lists PMID 23821053 in Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-07-03 (day precision). PeptideScanner associated the retained record with the identity slug semax. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Literature metadata · Tesamorelin
PubMed lists PMID 25358450 in Clinical pharmacokinetics as Clinical Trial, Phase I, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2015-03 (month precision). PeptideScanner associated the retained record with the identity slug tesamorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Literature metadata · KPV
PeptideScanner retained PubMed bibliographic metadata for PMID 34547895 at 2026-07-30T19:58:34.757Z. PubMed recorded a metadata revision date of 2021-10-21 and an Entrez history date of 2021-09-22. PeptideScanner associated this retained record with the identity slug kpv. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Literature metadata · KPV
PeptideScanner retained PubMed bibliographic metadata for PMID 22837805 at 2026-07-30T19:58:22.828Z. PubMed recorded a metadata revision date of 2021-10-21 and an Entrez history date of 2012-07-28. PeptideScanner associated this retained record with the identity slug kpv. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Regulatory · Dulaglutide
DailyMed lists Structured Product Labeling version 40 for the reviewed Dulaglutide label family with a published date of 2021-10-18. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Clinical trials · Abaloparatide
PeptideScanner retained ClinicalTrials.gov record NCT03710889 at 2026-07-30T19:57:27.406Z. Its registry update date was 2021-10-15, and PeptideScanner's reviewed identity mapping was abaloparatide.
Source: ClinicalTrials.gov ↗
Regulatory · Dulaglutide
DailyMed lists Structured Product Labeling version 39 for the reviewed Dulaglutide label family with a published date of 2021-10-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Clinical trials · Afamelanotide
PeptideScanner retained ClinicalTrials.gov record NCT00979745 at 2026-07-30T19:57:27.405Z. Its registry update date was 2021-10-12, and PeptideScanner's reviewed identity mapping was afamelanotide.
Source: ClinicalTrials.gov ↗
Literature metadata · Setmelanotide
PubMed lists PMID 33638809 in Drugs as Journal Article, Review, with publication-date metadata of 2021-02 (month precision). PeptideScanner associated the retained record with the identity slug setmelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Regulatory · Afamelanotide
DailyMed lists Structured Product Labeling version 4 for the reviewed Afamelanotide label family with a published date of 2021-10-04. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Clinical trials · Afamelanotide
PeptideScanner retained ClinicalTrials.gov record NCT04425746 at 2026-07-30T19:57:27.405Z. Its registry update date was 2021-10-01, and PeptideScanner's reviewed identity mapping was afamelanotide.
Source: ClinicalTrials.gov ↗
Regulatory · Abaloparatide
DailyMed lists Structured Product Labeling version 9 for the reviewed Abaloparatide label family with a published date of 2021-09-29. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Literature metadata · Setmelanotide
PubMed lists PMID 33787829 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, with publication-date metadata of 2021-03-31 (day precision). PeptideScanner associated the retained record with the identity slug setmelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Literature metadata · Setmelanotide
PubMed lists PMID 34544109 in The Medical letter on drugs and therapeutics as Journal Article, Review, with publication-date metadata of 2021-07-26 (day precision). PeptideScanner associated the retained record with the identity slug setmelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Regulatory · Linaclotide
DailyMed lists Structured Product Labeling version 28 for the reviewed Linaclotide label family with a published date of 2021-09-08. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Regulatory · Exenatide
The Federal Register published notice 2021-18928, attributed to FDA and its parent HHS department, on 2021-09-02. Its official title is “Proposal To Refuse To Approve a New Drug Application for ITCA 650 (Exenatide in DUROS Device); Opportunity for a Hearing,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide.
Source: Federal Register via GovInfo ↗
Safety · Dulaglutide
FDA's dated enforcement report D-0773-2021 lists Class II and source status Terminated for Eli Lilly & Company. PeptideScanner connects the report to reviewed application BLA125469 through exact openFDA application-number annotations.
Regulatory · Leuprolide + 1 more
The Federal Register published notice 2021-18072, attributed to FDA and its parent HHS department, on 2021-08-23. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Semaglutide.
Source: Federal Register via GovInfo ↗
Literature metadata · Dulaglutide
PubMed lists PMID 34153270 in The lancet. Diabetes & endocrinology as Journal Article, Comment, with publication-date metadata of 2021-06-18 (day precision). PeptideScanner associated the retained record with the identity slug dulaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Clinical trials · Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT03734627 at 2026-07-30T19:59:58.328Z. Its registry update date was 2021-08-16, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Regulatory · Leuprolide
The official Drugs@FDA dataset lists original submission 1 for ANDA 213829 with status AP dated 2021-08-13, and names leuprolide acetate among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Regulatory · Lixisenatide
DailyMed lists Structured Product Labeling version 16 for the reviewed Lixisenatide label family with a published date of 2021-08-09. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Literature metadata · Setmelanotide
PubMed lists PMID 33137294 in The lancet. Diabetes & endocrinology as Journal Article, Comment, with publication-date metadata of 2020-10-30 (day precision). PeptideScanner associated the retained record with the identity slug setmelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Clinical trials · Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT02023411 at 2026-07-30T20:02:09.392Z. Its registry update date was 2021-06-30, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Clinical trials · Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT00003653 at 2026-07-30T20:02:09.393Z. Its registry update date was 2021-06-23, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Clinical trials · Exenatide
PeptideScanner retained ClinicalTrials.gov record NCT01590433 at 2026-07-30T20:02:09.394Z. Its registry update date was 2021-06-23, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗
Regulatory · Semaglutide
DailyMed lists Structured Product Labeling version 1 for the reviewed Semaglutide label family with a published date of 2021-06-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Literature metadata · Semax
PubMed lists PMID 32737723 in Bulletin of experimental biology and medicine as Journal Article, with publication-date metadata of 2020-08-01 (day precision). PeptideScanner associated the retained record with the identity slug semax. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Regulatory · Semaglutide
The official Drugs@FDA dataset lists original submission 1 for NDA 215256 with status AP dated 2021-06-04, and names semaglutide among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Safety · Linaclotide
FDA's dated enforcement report D-0417-2021 lists Class II and source status Terminated for Cardinal Health Inc. PeptideScanner connects the report to reviewed application NDA202811 through exact openFDA application-number annotations.
Safety · Semaglutide
FDA's dated enforcement report D-0536-2021 lists Class II and source status Terminated for Cardinal Health Inc. PeptideScanner connects the report to reviewed application NDA213051 through exact openFDA application-number annotations.
Regulatory · Octreotide
The Federal Register published notice 2021-11575, attributed to FDA and its parent HHS department, on 2021-06-02. Its official title is “Determination That SANDOSTATIN (Octreotide Acetate) Injection, Equal to 0.2 Milligrams Base/Milliliter and Equal to 1 Milligrams Base/Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Octreotide.
Source: Federal Register via GovInfo ↗
Literature metadata · Abaloparatide
PubMed lists PMID 32665529 in Menopause (New York, N.Y.) as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2020-10 (month precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Regulatory · Abaloparatide
DailyMed lists Structured Product Labeling version 8 for the reviewed Abaloparatide label family with a published date of 2021-05-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Clinical trials · Glucagon
PeptideScanner retained ClinicalTrials.gov record NCT04347252 at 2026-07-30T20:03:05.484Z. Its registry update date was 2021-05-14, and PeptideScanner's reviewed identity mapping was glucagon.
Source: ClinicalTrials.gov ↗
Clinical trials · Exenatide
PeptideScanner retained ClinicalTrials.gov record NCT02685852 at 2026-07-30T20:03:05.483Z. Its registry update date was 2021-05-06, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗
Clinical trials · Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT01292252 at 2026-07-30T20:03:05.485Z. Its registry update date was 2021-05-03, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Regulatory · Plecanatide
DailyMed lists Structured Product Labeling version 11 for the reviewed Plecanatide label family with a published date of 2021-04-27. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Safety · Liraglutide
FDA's dated enforcement report D-0618-2021 lists Class II and source status Terminated for Novo Nordisk Inc. PeptideScanner connects the report to reviewed application NDA206321 through exact openFDA application-number annotations.
Safety · Liraglutide
FDA's dated enforcement report D-0622-2021 lists Class II and source status Terminated for Novo Nordisk Inc. PeptideScanner connects the report to reviewed application NDA022341 through exact openFDA application-number annotations.
Regulatory · Linaclotide
DailyMed lists Structured Product Labeling version 27 for the reviewed Linaclotide label family with a published date of 2021-04-20. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Regulatory · Dulaglutide
DailyMed lists Structured Product Labeling version 38 for the reviewed Dulaglutide label family with a published date of 2021-04-16. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Regulatory · Linaclotide
DailyMed lists Structured Product Labeling version 26 for the reviewed Linaclotide label family with a published date of 2021-04-16. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Literature metadata · Abaloparatide
PubMed lists PMID 33778325 in JBMR plus as Journal Article, with publication-date metadata of 2021-02-04 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Regulatory · Bremelanotide + 1 more
The Federal Register published notice 2021-06202, attributed to FDA and its parent HHS department, on 2021-03-25. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Bremelanotide and Octreotide.
Source: Federal Register via GovInfo ↗
Clinical trials · Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT02616003 at 2026-07-30T20:05:17.854Z. Its registry update date was 2021-03-23, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Clinical trials · Afamelanotide
PeptideScanner retained ClinicalTrials.gov record NCT04704713 at 2026-07-30T20:05:17.854Z. Its registry update date was 2021-03-19, and PeptideScanner's reviewed identity mapping was afamelanotide.
Source: ClinicalTrials.gov ↗
Clinical trials · Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT01338987 at 2026-07-30T20:05:17.853Z. Its registry update date was 2021-03-18, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Clinical trials · Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT03466021 at 2026-07-30T20:05:17.854Z. Its registry update date was 2021-03-16, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Literature metadata · Dulaglutide
PubMed lists PMID 32141343 in Current medical research and opinion as Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2020-03-19 (day precision). PeptideScanner associated the retained record with the identity slug dulaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Regulatory · Plecanatide
DailyMed lists Structured Product Labeling version 9 for the reviewed Plecanatide label family with a published date of 2021-02-23. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Literature metadata · Abaloparatide
PubMed lists PMID 33615100 in JBMR plus as Published Erratum, with publication-date metadata of 2020-11-03 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Regulatory · Linaclotide
The official Drugs@FDA dataset lists original submission 1 for ANDA 209564 with status AP dated 2021-02-09, and names linaclotide among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Clinical trials · Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT02176382 at 2026-07-30T20:06:10.499Z. Its registry update date was 2021-02-09, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Literature metadata · Dulaglutide
PubMed lists PMID 30410215 in Australian prescriber as Journal Article, Review, with publication-date metadata of 2018-09-11 (day precision). PeptideScanner associated the retained record with the identity slug dulaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Regulatory · Dulaglutide
DailyMed lists Structured Product Labeling version 37 for the reviewed Dulaglutide label family with a published date of 2021-01-25. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Clinical trials · Lanreotide
PeptideScanner retained ClinicalTrials.gov record NCT03012594 at 2026-07-30T20:07:13.495Z. Its registry update date was 2021-01-15, and PeptideScanner's reviewed identity mapping was lanreotide.
Source: ClinicalTrials.gov ↗
Clinical trials · Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT04206618 at 2026-07-30T20:07:13.493Z. Its registry update date was 2021-01-12, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Literature metadata · Lixisenatide
PubMed lists PMID 30656523 in Diabetes therapy : research, treatment and education of diabetes and related disorders as Journal Article, with publication-date metadata of 2019-01-17 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗